Rio’s share price rocked by fraud charges

Published 20-OCT-2017 10:30 A.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Rio Tinto has featured heavily in this week’s headlines after the Securities and Exchange Commission charged the company and two of its former executives with fraud.

The SEC claims that the company, its former chief executive officer Tom Albanese and former chief financial officer Guy Elliot, withheld key information in regards to its Riversdale Mining acquisition.

According to the US regulator, the accused “sought to hide or delay disclosure of the nature and extent of the adverse developments from Rio Tinto’s Board of Directors, Audit Committee, independent auditors, and investors.”

This is not the first indiscretion under Albanese’s tenure, with the former chief executive disclosing astronomical losses for Rio Tinto at its Alcan project shortly before the alleged fraud began.

Tom Albanese

Tom Albanese resigned in 2013

Albanese bought out aluminium producer Riversdale Mining for US$38.1 billion in 2007, but by 2013 a total of US$25 billion in write-downs had been accrued on the merger, making it one of the worst mining deals of all time.

It’s believed the catastrophic outcome of the Alcan deal was the catalyst for the alleged fraud. The Mozambique Riversdale Mining play, which cost Rio Tinto US$3.9 billion in 2011, was sold for just US$50 million in 2014.

Incorrect evaluations about the quality and quantity of the coal onsite meant that substantial setbacks were experienced at the asset almost immediately.

The mining titan planned to ferry coal from the new site via the nearby Zambezi River, but after the Mozambique government rejected its proposal in December 2011, only five percent of the initial projection could be retrieved.

“Rio Tinto raised $5.5 billion from US investors, approximately $3 billion of which was raised after May 2012, when executives at Rio Tinto Coal Mozambique had already told Albanese and Elliott that the subsidiary was likely worth negative $680 million,” the SEC said.

Former Rio Tinto CFO Guy Elliot

The alleged fraud is reported to have continued until January 2013, when an unnamed executive in the company’s Technology & Innovation Group discovered that Rio Tinto had inflated the coal asset by over 80 per cent.

An internal review triggered Albanese’s resignation in 2013, which led to the company underwriting the assets by more than US$3 billion upon his departure.

“Rio Tinto and its top executives allegedly failed to come clean about an unsuccessful deal that was made under their watch,” SEC co-director Steven Peikin said. “They tried to save their own careers at the expense of investors by hiding the truth.”

When pressed about yesterday’s developments, Albanese responded stating, “There is no truth in any of these charges.”

Rio Tinto also denied any wrongdoing, affirming that it would defend itself against charges.

“Rio Tinto believes that the SEC case is unwarranted and that, when all the facts are considered by the court, or if necessary by a jury, the SEC’s claims will be rejected,” the company said in its statement to the Australian Securities Exchange. Elliot’s spokesperson has denied the allegations and will contest charges.

Andrew Watson, who is the head of class actions at Maurice Blackburn, believes there is ‘potential’ for Rio Tinto to face a class action over the allegations.

Rio Tinto (ASX:RIO) closed 3.5 per cent lower at $69.12 on the back of the news.

This article is General Information and contains only some information about some elements of one or more financial products. It may contain; (1) broker projections and price targets that are only estimates and may not be met, (2) historical data in terms of earnings performance and/or share trading patterns that should not be used as the basis for an investment as they may or may not be replicated. Those considering engaging with any financial product mentioned in this article should always seek independent financial advice from a licensed financial advisor before making any financial decisions.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free